



Norman Stockbridge, MD, PhD received his MD in 1978 and PhD in Physiology in 1981 from Duke University. He received post-doctoral training at Duke and New York Medical College. Dr. Stockbridge was a Staff Fellow at the NIH National Eye Institute. In 1985 he joined the faculty of the Department of Surgery at University of Alberta doing basic cellular electrophysiology research.

Dr. Stockbridge joined FDA's Division of Cardio-Renal Drug Products in 1991, serving a medical officer, medical team leader, and deputy division director, prior to becoming the division director. He is currently the Director of the Division of Cardiovascular and Renal Products within the FDA Center for Drug Evaluation and Research.

This division regulates approval of the following drugs: agents for the prevention of restenosis, agents for treating renal disease, agents used for intermittent claudication, agents used in hypotension and shock, angiographic diagnostic agents, angiotensin converting enzyme inhibitors, antianginal agents, anti-arrhythmics, anti-hypertensive agents, antiotensin II receptor antagonists, antiplatelet drugs, B-blockers B1 selective, beta blocking agents, botanical products for cardiovascular indication, calcium channel blockers, cardiovascular/diagnostics, central alpha-2 agonists, coronary vasodilators, diuretics and renal tubule inhibitors, neutral endopeptidase/angiotensin converting enzyme inhibitors, peripheral vasodilators, potassium channel openers, and potassium salts.